Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-05-28
1998-12-29
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544360, 544366, 544396, A01N 4360, C07D40100, C07D40300, C07D24104
Patent
active
058542493
ABSTRACT:
A method for the treatment or prophylaxis of one or more conditions or disorders selected from the group consisting of physiological pain, diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depressioysema, apnea, cognitive disorders and gastrointestinal disorders, comprising administration to a subject in need of such treatment or prophylaxis, of a diarylmethylpiperazine or piperidine opioid compound.
REFERENCES:
patent: 2630435 (1953-03-01), Baltzly et al.
patent: 4518711 (1985-05-01), Hruby et al.
patent: 4816586 (1989-03-01), Portoghese
patent: 5574159 (1996-11-01), Chang et al.
patent: 5658908 (1997-08-01), Chang et al.
Pakarinen, "Effects of Convulsant Agents on Learning and Memory in Squirrel Monkeys," Dissertation Abstracts International, 54(01B), 189 (Mar. 31, 1993-13 entered in the Louisiana State University online catalog).
Calderon et al., "Synthesis and Absolute Configuration of Optically Pure Enantiomers of (.+-.)-BW373U86, A Nonpeptidic.delta.-Opioid Receptor Agonist," College on Problems of Drug Dependence, Inc., Fifty-fifth Annual Scientific Meeting, Toronto, Canada, Poster Presentation, (Jun. 12-17, 1993).
Selley, "BW373U86 A Non-peptide .delta.-Opioid Agonist With Novel Receptor-G-Protein-Mediated Actions," Meeting of the International Narcotics Research Conference (INRC). Skoevde, Sweden, Abstract (Jul. 11-16, 1993).
Comer, "BW373U86: Behavioral Pharmacology of a Putative Non-Peptide, Systemically-Active Delta Opioid Agonist," Dissertation Abstracts International, 53(5b). 2578 (Jul. 1, 1992--entered in the University of Michigan online catalog).
Chang, "Identification of a Novel, Potent and Selective Non-Peptidic Delta-selective Agonist BW373U86," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Comer, "BW373U86: Delta-receptor-mediation of Convulsions and Refractoriness," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Dykstra, "Behavioral Effects of a Novel and Selective Opioid Delta Agonist in the Monkey," Meeting of the International Narcotics Research Conference (INRC). Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Porreca, "Multiple Opioid Delta Receptors," Meeting of the International Narcotics Research Conference (INRC), Keystone, Colorado, Oral Presentation, (Jun. 23-27, 1992).
Boradbent et al., "Role of Opioid Receptor Subtypes in the Discriminative Stinulus Effects of Cocaine," Meeting of the International Narcotics Research Conference (INRC), Keystone, Colorado, Abastact, (Jun. 23-27, 1992).
Dworkin et al., "Effects of .delta.-Opiate Agonist and Antagonists on Cocaine and Heroin Self Administration in Rats," Meeting of the International Narcotics Research conference (INRC). Keystone, Colorado, Abstract (Jun. 23-27, 1992).
Dykstra, et al., "Effects of a Novel Delta Opioid Agonsit in Squirrel Monkeys Responding Under a Schedule of Shock Tritration." Meeting of the International Narcotics Research Conference (INRC), Keystone, Colorado, Abstract (Jun. 23-27, 1992).
Lee et al., "A Non-peptide Delta-Opioid Receptor Agonist BW373U86 Suppresses Naloxone-precipated Morphine Abstience," Meeting of the International Narcotics Research Conference (INRC), Keystone, Colorado, Abstract (Jun. 23-27, 1992).
Porreca et al., "Pharmacology of Multiple Opioid Delta Receptors," National Institute on Drug Abuse Research Monograph Series 132, Problems of Drug Dependence, 1992: Proceeding of the 54th Annual Scientific Meeting, 430-436 (1993).
Iwamoto et al., "Calcium Antagonism, by KB-2796, a New Diphenylpiperazine Analogue, in Dog Vascular Smooth Muscle." J. Pharm. Pharmacol., 43, 535-539 (1991).
Goenechea et al., "Untersuchungen zur Biotransformation von Meclozin im Menschlichen Korper," J. Clin. Chem. Clin. Biochem., 26, 105-115 (1988)--See Specification, p. 4, last paragraph and Chemical Abstracts 108: 215746g.
Iwamoto et al., "Effects of KB-2796, a New Calcium Antagonist, and Other Pharmacol. 48, 241-247 (1988).
Natsuka et al., "Synthesis and Structure-Activity Relationships of 1-Substituted 4-(1,2-Diphenylethyl)piperazine Derivatives having Narcotic Agonist and Antagonist Activity," J. Med. Chem., 30(10), 1779-1787 (1987).
Meuldermas et al., "Plasma Levels, Biotransformation and Excretion of Oxatomide (R 35 443) in Rats, Dogs and Man," Xenobiotica, 14(6), 445-462 (1984).
Krishnamurthy, "A Highly Efficient and General N-Monomethylation of Functionalized Primary Amines Via Formylation-Borane: Methyl Sulfide Reduction," Tet. Let., 23(33), 3315-3318 (1982).
Lord et al., "Endogenous Opioid Peptides: Multiple Agonists and Receptors,"Nature, 267, 495-499 (1977).
Chang et al., "A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW 373U86", J. Pharmacol. Exp. Ther., 267, 852-857 (1993).
Childers et al., "BW373U86: A Non-peptidic .delta.-Opioid Agonist With Novel Receptor-g Protein-mediated Actions in Rat Brain Membranes and Neuroblastoma Cells", Molec. Pharmacol., 44,827-834 (1993).
Comer et al., "Convulsive Effects of Systemic Administration of the Delta Opioid Agonist BW373U86 in Mice", J. Pharmacol. Exp. Ther., 267,888-895 (1993).
Comer et al., "Discriminative Stimulus Effects of BW373U86: A Non-peptide Ligand With Selectivity for Delta Opioid Receptors", J. Pharmacol. Exp. Ther., 267, 866-874 (1993).
Dykstra et al., "A Novel Delta Opioid Agonist, BW373U86, in Squirrel Monkeys Responding Under a Schedule of Shock Titration", J. Pharmacol. Exp. Ther., 267, 875-882 (1993).
Lee et al., "A Nonpeptidic Delta-opioid Receptor Agonist, BW373U86, Attenuates the Development and Expression of Morphine Abstinence Precipitated by Naloxone in Rat . . .", J. Pharmacol. Exp. Ther., 267, 883-887 (1993).
Negus et al., "Effects of Opioid Agonists Selective for Mu, Kappa and Delta Opioid Receptors on Schedule-controlled Responding in Rhesus Monkeys: Antagonism by Quadazocine", J. Pharmacol. Exp. Ther., 267, 896-903 (1993).
Wild et al., "Binding of 373U86, A Non-peptidic .delta.-Opioid Receptor Agonist, is Not Regulated by Guanine Nucleotides and Sodium", Eur. J. Pharmacol.-Molec. Pharmacol., Section 246, 289-292 (1993).
Wild et al., "Antiociceptive Actions of BW373U86 in the Mouse", J. Pharmacol, Exp. Ther. 267, 858-865, 1993.
Xu et al., "Differential Binding of Opioid Peptides and Other Drugs to Two Subtypes of Opioid.delta..sub.ncx Binding Sites in Mouse Brain: Further Evidence of .delta. Receptor Heterogeneity", Peptides 14, 893-907 (1993).
Boswell Grady Evan
Bubacz Dulce Garrido
Chang Kwen-Jen
Collins Mark Allan
Davis Ann Otstot
Barrett William A.
Delta Pharmaceuticals, Inc.
Hultquist Steven J.
Ngo Tamthom T.
Shah Mukund J.
LandOfFree
Opioid diarylmethylpiperazines and piperidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opioid diarylmethylpiperazines and piperidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid diarylmethylpiperazines and piperidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1425103